Indian drug approvals drop by 28% yoy in US in Q1 FY’20

The first quarter of the current financial year saw abbreviated new drug applications (ANDA ) received by Indian pharma firms dipping by 28%. While during 2017-18, 155 Indian firms received approvals by US Food and Drug Administration (USFDA); this year only 111 firms got the green chit by the regulatory agency. The country’s share of ANDA approvals given by the US Food and Drug Administration (USFDA) has declined from 43% in Q4 of FY19 to 33% in Q1 FY20. Increased scrutiny on firms is being seen as the reason behind this development.